Jade Biosciences (JBIO) Payables (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Payables data on file, last reported at $4.0 million in Q1 2026.

• Quarterly Payables rose 5666.67% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 5666.67% YoY) and the FY2025 annual result came in at $2.2 million, up 66.74% from the prior year.
• Payables advanced to $4.0 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Payables ranged from a high of $7.6 million in Q2 2025 to a low of $69000.0 in Q1 2025.
• A 5-year average of $3.1 million and a median of $2.9 million in 2022 frame the typical range for Payables.
• Annual changes were most pronounced in 2025 — Payables slumped 97.92% — and 2026, when it surged 5666.67%.
• Tracing JBIO's Payables over 5 years: stood at $2.6 million in 2022, then dropped by 6.95% to $2.4 million in 2023, then plunged by 46.16% to $1.3 million in 2024, then jumped by 66.74% to $2.2 million in 2025, then soared by 84.98% to $4.0 million in 2026.
• The last three Payables figures came in at $4.0 million (Q1 2026), $2.2 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.